

ESMO Checklist: Quality Issues Concerning Newly Diagnosed Prostate Cancer Patient Related Treatment Workflow

Tick the box and insert the date as you have dealt with every task listed below, as appropriate. In case you use the template, you can also insert and save data directly on the PDF file.

PATIENT'S PERSONAL DATA				
Last Name:		First Name:		
Date of birth: __/__/__		Gender:		
DATE OF REFERRAL/1ST CONSULTATION: __/__/__				
__/__/__ MEDICAL HISTORY AND RISK FACTORS				
Past medical history and vascular risk factors:				
Past surgical history:				
Concurrent medication:				
Allergies:				
Smoking history: __pack/y from age__ to age__				
Alcohol consumption:				
Normal weight:		Height:		BMI:
__/__/__ PRESENT MEDICAL CONDITIONS				
Main symptoms:				
Weight loss:				
ECOG Performance Status:				
Pain:				
Other relevant clinical conditions:				
__/__/__ DIAGNOSIS AND CLINICAL STAGING				
__/__/__ DRE				
__/__/__ PSA		One-off	Repeat	
		Total PSA	Free PSA	PSA Doubling Time
__/__/__ Endorectal ultrasound				
__/__/__ Pelvic MRI				
Nodal staging (intermediate/high risk disease):				
__/__/__ CT				
__/__/__ MRI				
__/__/__ Whole body MRI				
__/__/__ Pelvic node dissection				
Staging for metastases (intermediate/high risk disease):				
__/__/__ Technetium bone scan and thoraco-abdominal CT scan				
__/__/__ Whole body MRI				
__/__/__ TNM stage and grade				
__/__/__ HISTOLOGICAL ANALYSIS				
Biopsy				
Gleason score				
BRCA status (if available)				
BIOMARKERS ANALYSIS				
Family history of prostate cancer: consider germline testing for BRCA2/DDR genes				
Metastatic prostate cancer: consider germline testing for BRCA2/DDR genes				
Metastatic castration refractory setting: Consider tumour testing for homologous recombination genes and mismatch repair defects (or microsatellite instability)				
Patients with pathogenic mutations in cancer-risk genes identified through tumour testing should be referred for germline testing and genetic counselling				

___/___/___ RISK CLASSIFICATION			
Localised disease classification		Low risk	Intermediate risk
Metastatic disease:	YES	Low volume	High volume
	NO		
Germline testing BRCA2 and DDR genes:	YES		
	NO		
Tumor testing for HRD and MSI:	YES		
	NO		
<i>Risk Grouping: - Low (T-1T2a and GS GS≤6 and PSA ≤10 - Intermediate (T2b/c and/or GS7 and/or PSA 20-10) - High (≥T3a or GS 10-8 or PSA >20)</i>			

Timeline for further work-up has been checked and it is tight enough

___/___/___	MDT discussion and decision Surgery adjuvant therapy Neo-adjuvant medical treatment Radiation therapy Supportive and palliative care Enrolment in a clinical trial
-------------	--

___/___/___ Treatment options have been discussed with the patient and strategy accepted

COMPILER INFORMATION

Name:	Date: ___/___/___
Comments:	